Lopez-Pedrera, C.Munoz-Barrera, L.Escudero Contreras, A.Aguirre-Zamorano, M. A.Ortiz Buitrago, P.Lopez-Medina, C.Calvo Gutierrez, J.Ortega Castro, R.Pilar, F. U.Sanchez-Pareja, I.Abalos-Aguilera, M. C.Barbarroja Puerto, N.Collantes Estevez, E.Perez-Sanchez, C.2023-05-032023-05-032022-06-01Lopez-Pedrera C, Muñoz-Barrera L, Contreras AE, Aguirre-Zamorano MÁ, Buitrago PO, López-Medina C, et al. POS0058 IDENTIFICATION OF NOVEL BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC AUTOIMMUNE DISEASES THROUGH NEXT GENERATION PROTEOMICS. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):245.2-2450003-4967http://hdl.handle.net/10668/20121Background: Systemic autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are characterised by aberrant autoimmune and inflammatory processes, which are directly associated with the development and progression of these disorders. Novel biomarkers associated with the severity of these diseases are needed to better characterise and monitor their progression as well as to develop new and more effective therapeutic strategies.enArthritis, rheumatoidLupus erythematosus, systemicReverse transcriptase polymerase chain reactionCorrelation of dataDisruptive technologyGene ontologyProteomicsAntibodiesBiomarkersconference outputopen accessAnticuerposBiomarcadoresOntología de genesProteómicaTecnología disruptiva10.1136/annrheumdis-2022-eular.47331468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/245.2.full.pdf850279000375